TABLE 4.
Description of SARS-CoV-2 vaccine trial efficacy and viral neutralization of B.1.1.7, 501Y.V2, and P.1 variants vs. preexisting variants (Abdool Karim and de Oliveira, 2021).
| Vaccine |
Neutralization by pseudovirion/Live viral plaque assay |
||||
| Preexisting variants with efficacy in preventing clinical/severe COVID-19 (%) | B.1.1.7 variant | 501Y.V2 variant | P.1 variant | References | |
| BNT162b2 (Pfizer) | 95/90 | Decrease by 2× | Decrease by ≤ 6.5× | Decrease by 6.7× | Polack et al., 2020; Garcia-Beltran et al., 2021; Wang et al., 2021 |
| mRNA-1273 (Moderna) | 94/100 | Decrease by 1.8× | Decrease by ≤ 8.6× | Decrease by 4.5× | Baden et al., 2021; Garcia-Beltran et al., 2021; Shen et al., 2021; Wang et al., 2021; Wu et al., 2021 |
| NVX-CoV2373 (Novavax) | 89/100 | Decrease by 1.8× | NA | NA | Shen et al., 2021 |
| Sputnik V (Gamaleya) | 92/100 | NA | NA | NA | Logunov et al., 2021 |
| AZD1222 (AstraZeneca) | 67/100 | NA | Decrease by ≤ 8.6× to complete immune escape | NA | Madhi et al., 2021; Voysey et al., 2021 |
| BBIBP-CorV (Sinopharm) | 79/NA | NA | Decrease by 1.6× | NA | Huang et al., 2021 |